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The last 25 years have seen amazing progress in 
transplantation-from the development of tech-
niques for immunosuppression to methods for organ 
removal and preservation. Our distinguished authors 
focus on these developments and discuss how the 
momentum seen during the last quarter century can 
be accelerated. 
Introduction 
The success of whole organ transplantation has been one 
of the least expected events in the history of medicine. In 
1961 the Nobe l Laureate Burnet wrote in the New England 
Journal 0/ Medicine that "much thought has been given 
to ways by which tissues or organs not genetically and ant i-
genically identical with the patient might be made to sur-
vive and function in the alien environment. On the whole, 
the present outlook is highly unfavorable to success . . . " 1 
This pessimistic view was published more than a year before 
the avalanche of successful clinical renal transplan tat ions 
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in 1962 and 1963 that extended such procedures beyond 
the occasional transplantation cases between identical and 
fraternal twins in the mid- and late 1950s. 
The first sporadic clinical efforts at renal transplantation 
preda ted the watershed years of 1962 and 1963 by a half 
century. The first known attempts at clinical renal tran s-
plantation by vasc ular anastomoses were made between 
1906 and 1923 without immunosuppress ion with sheep, 
pig, goat, and subhuman primate donorsK ~ · 1 one of the 
kidneys functioned and the human recipients died within 
a few hours to nine days later. 
Despite the climate o f ignorance in wh ich the trials were 
conducted, some principles were clearly delineated. The 
applicability of vascular suture techniques and even the 
possibility of using pelvic implantation sites were either 
envisioned or actually practiced. No further clinical renal 
heterotransplantations (animal to man) were tried again 
until 1963. 
The first human-to-human kidney transplantation 
(homotransplantation) was reported in 1936 by the Russ ian 
Voronoy, who transplanted a kidney from a cadaver donor 
of B + blood type to a recipient of 0 + blood type, violating 
what are now well accep ted rules of tissue tran sfer." The 
patient died 48 hours later without making urine. The 
possibility that there would be an immune barrier to success 
was apparently not obvious to ea rly clinicians. This realiza-
tion awaited the classical studies of Medawar with rodent 
skin grafts, which established the immunologic basis of 
reject ion. ' 
I n the 20 years following Voronoy's case, sporadic furth er 
efforts at renal homotransplantation were made without 
effective immunosuppression as documented by Groth, ] 
The heterotopic extraperitoneal technique of renal trans-
plantation, which became today's standard, was developed 
by the French surgeons Dubost.6 KUSS, 7 and ServelleB and 
their associates. Merrill observed the extraperitoneal9pera-
tion while visiting France in the early 1950s, as was men-
tioned by Hume et al,9 and the technique was adopted for 
the first identical and fraternal twin cases performed in 
Boston . lo.11 
None of the foregoing efforts, singly or together, had 
major significance in the pro-
cedure's development as the 
principal ingredients of organ 
t ransplantat ion-namely 
immunosuppression , tissue 
matching, and organ pro-
curement and preservat ion 
-were either unknown or 
undeveloped . 
This discussion will focus 
on the astonishing develop-
ments in transplantation dur-
ing the last quarter century, 
speculate about how the 
momentum of this progress 
can be sustained and accel-
erated, and discuss how gov-
ernment policies have intlu-
enced past events or could 
influence further develop-
ments. Although the princi-
ples of organ transplantation 
were developed with the sim-
ple kidney model, it was natu-
ral that transplantation tech-
nology would be applied to 
the grafting of other organs, 
including the liver, heart, 
lung, and pancreas. 
Immunosuppression 
The Earliest Efforts 
Special Feature 
and 1963 with the marriage of corticosteroid theral3Y, usual-
ly prednisone or prednisolone, to baseline therapy with 
azathioprine. 2.21 The value of this synergistic drug combi-
nation was promptly confirmed, 22 permitting funda -
mental observations including the fact that rejection was 
a reversible process. A change in the relation between the 
graft and the host often occurred in the time after the opera-
tion, permitting eventual re-
duction of drug doses. Pa-
tients who did not require 
chronic high-dose cortico-
steroid therapy to retain their 
grafts could return to useful 
social and vocational func-
tion without the fear of 
immunological invalidism. 
Double-drug therapy with 
azathioprine and prednisone 
remained the gold standard 0 f 
transplantation for many years . 
However, consistently 
good transplantation results 
could be obtained only with 
transplantation from blood 
relatives, and even then only 
with good tissue matching. 
This unsatisfactory situation 
was a great stimulus to search 
for better immunosuppres-
sive regimens. 
By 1960 the possibility of 
weakening the recipient's 
immune process with corti-
costeroids, 12 total body irra -
Dr Starzl, Director of Transplant Services at Pres-
byterian-University Hospital of Pittsburgh, proceeds 
with a liver transplantation. 
Triple-Drug Therapy 
Consequently, modifications 
of or additions to the original 
double-drug treatment were 
made as summarized else-
where23 during the next 16 
years. Most modifications 
were designed to blunt the 
attack of lymphocytes, which 
were recognized as the medi-
ators of rejection. The most 
diation, 13.14 the cytotoxic drug 6-mercaptopurine, 15.16 or its 
imidazole derivative, azathioprine,17 had been established 
in animals . Sporadic attempts to use these techniques for 
renal homotransplantation in humans were so unsuccess-
fUp ·II .18. 19.20 that it was widely thought that the use of 
immunosu ppression to prevent rejection inevitably led to 
immunologic invalidism and lethal infections. 
Double-Drug Therapy 
Renal transplantation became a practical reality in 1962 
significant addition was the 
use of antilymphocyte globulin (ALG) as an adjunct to 
azathioprine and prednisone.24 The A LG consisted of 
polyclonal antibodies against human lymphoid tissue; the 
antibodies were raised in horses, rabbits, goats, or other 
animals by immunizing them to human lymphocytes. 
When thymic lymphocytes were used for immunization, 
the product was called antithymocyte globulin (ATG). The 
antibody-containing globulin was extracted, purified, and 
made ready for intramuscular or intravenous use. Usually, 
ALG was administered during the first few weeks or 
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months after transplantation. 
In spite of its great potential value, polyclonal ALG was 
not universally employed as a part of the antirejection 
armamentarium because of several limiting features, in-
cluding the fact that its quality could not be standardized. 
This latter problem, as well as other deficiencies, was elimi-
nated with the new hybridoma technology introduced by 
Kohler and Milstein25 ; when hybridoma cells were injec-
ted into the peritoneum of mice, a homogeneous or mono-
clonal antihuman-lymphocyte antibody was produced. 
Clinical medicine therapy with monoclonal antibodies was 
introduced by Cosimi et aP6; they used the so-called 
OKT3 (trademark, Ortho Pharmaceutical) antibodies, 
which selectively deplete mature T-Iymphocytes. The objec- . 
tive of this therapy was to reverse kidney graft rejection 
previously nonresponsive or poorly responsive to cortico-
steroid therapy. O KT3 therapy has proved to be of value, 
and it was released in 1986 for general use in the United 
States by the Food and Drug Administration (FDA). 
It was widely thought that the use of 
immunosuppression to prevent rejection 
inevitably led to immunologic invalidism 
and lethal infections. 
In spite of the encouraging results with the foregoing 
drugs and drug combinations, the margin between effect ive 
and toxic immunosuppression was still too narrow. W hole 
organ trans planta tion remained an unpredictable and dan -
gerous undertaking, especially if cadaver donors were used. 
Co nseq uen tly, the field had a relative growth arrest 
th roughout the 1970s, and there seemed to be little ho pe 
that transplantation of cadaver extrarenal organs, such as 
the liver or heart, could be considered on a large scale. Such 
pessimism was dispelled with the arrival of cyclosporine. 
The Cyclospori ne Era 
The im munosuppress ive qualities of this fungus extract 
were delineated by Borel et a(27 of Switzerland, and its 
first cl inical trials for use in solid organ transplanta tion 
were carried out by Caine and his associates in Cambridge, 
E ngland, beginning in the spring of 1978.28 In late 1979, 
a large trial that systematically combined cyclosporine with 
steroids29 was begun at the University of Colorado and 
later transferred to the University of Pittsburgh. This com-
bination therapy greatly improved the ability to control 
cadaver kidney rejection compared with any therapy in the 
past. 10 Almost overnight a worldwide avalanche o f act iv-
ity began in renal as well as extra renal transplantation pro-
grams, and the same drug combination was exploited 
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promptly for hepatic21 and cardiac11.l2 transplantation . 
The FDA released cyclosporine for general use in the United 
States in November 1983. 
In all programs cyclosporine administration is carefully 
guided by monitoring blood levels of the drug, necessitating 
the introduction of new and sophisticated radioimmuno-
assay (RIA) or high performance liquid chromatography 
(HPLC) techniques in clinical pathology laboratories. 
Organ Procurement and Preservation 
Practical immunosuppression was not perceived as feasible 
until the synergism of azathioprine and steroids was dem-
onstrated with startling clarity in 1962 and 1963. A similar 
void existed at that time in organ procurement and preser-
vation, as standard techniques did not exist for the removal 
of organs from either living or cadaver donors. Little 
thought or experimentation had been devoted to ways with 
which to treat the organ from the time of its removal to 
revascularization in the recipient. There was almost no 
understanding by the medical and legal professions, much 
less the public at large, of the conditions that should govern 
such activities. 
The Principle of Core Coo ling 
The potential benefit of lowering the temperature of an 
excised organ was grasped instinctively by early researchers. 
In som of the most deliberate applications of cooling that 
occurred almost 30 years ago, intestinal and cardiac grafts 
were preserved by simple immersion in ice-cold sal ine in 
Owen Wangensteen's laboratory at the University of Min-
nesota. However, even such inefficient attempts a t surface 
cooling were not made in any of the identical twin renal 
transplantations performed through 1962. 
A far more effective way to cool an organ is by in fusion 
of a cold so lution into its blood supply. This simple con-
cept-core cooling-was introduced into the laboratory 
almost 30 years ago to make possible li ver transplantation 
in dogs. JJ Without core cooling, liver transplantation was 
not possible; with core cooling, usually through the portal 
vein, success became the rule. Such clear evidence prompted 
the clinical application of core cooling for transplantation 
of the kid ney2 and all other organs. 
Even today, the intraoperative infusion of cold fluids is 
the essential first step to effective organ removal and preser-
vation. The overriding objective with all organ transplanta-
tion is avoidance of warm ischemia. This is achieved by 
carefully timed and controlled in situ infusion of cold solu-
tions into anatomical regions, the limits of which are 
defined by preliminary dissection of the abdominal and 
thoracic aorta . 
Organ graft cooling by the intravascular infusion of 
chilled solutions at the time of circulatory arrest increases 
the duration of organ viability and allows unhurried appli-
cation, if desired, of other, more sophisticated organ preser-
vation measures. Different solutions, for example, may be 
used; lactated Ringer's solution has low potassium content 
and is nearly isotonic. Chilled special solutions with an elec-
trolyte composition similar to that in cells were shown in 
1969 by Collins, Bravo-Shugarman, and Terasaki 34 to 
extend the permissible limit of cold renal ischemia beyond 
that achievable with isotonic solutions. The same effect has 
also been shown with donor livers.35 Cardiac surgeons 
have cooled the heart with various cardioplegic solutions 
having potassium concentrations of 20 to 30 mEq/ L. 
Procedures for Multiple Organ Removal 
Until 1981, transplantation of extrarenal organs was a rare 
event, and one that was confined to a handful of institu-
tions. Although renal transplant surgeons were concerned 
that removal of the liver and heart could damage kidneys 
from cadaver renal donors, these anxieties were muted by 
the small number of cases involved. However, by late 1981 
it became obvious that liver and thoracic organ transplant 
proced ures were becoming widespread and that a method 
of multiple organ procurement would be required so that 
kid neys, liver, heart, and lung, or various combinations o f 
the e organs, could be removed without jeopardizing any 
individ ual organs. 
Little thought or experimentation had 
been devoted to ways with which to treat 
the organ from the time of its removal to 
revascularization in the patient. 
Such a system was developed at the University of Pitts-
burgh's a ffiliated hospitals, and, at the request of the US 
Surgeon General C. Everett Koop, MD, the technique was 
described in detaip6; Preliminary dissection of the great 
vessels of the abdomen and chest of the donor is performed 
so that the organs to be removed can be core cooled in situ 
with cold intra-aortic and intraportal infusates, once the 
aorta has been crossclamped at preplanned levels. This 
technique was adopted as a worldwide standard almost 
overnight. A simplified modification of this o riginal 
procurement procedure has since come into use; it entails 
virtually no preliminary dissection of any of the organs 
to be removedY All organs are cooled in situ, after which 
they are rapidly removed by dissection in a bloodless field. 
The incidence of well-functioning donor kidneys, livers, 
and hearts has been better with this simplified method than 
with previous ones. 
The collegiality between collaborating transplantation 
groups (often from different cities) has been greatly im-
proved with the use of the rapid procurement operation. 
Furthermore, the new procedure can usually be carried out 
in less than 60 minutes from beginning to end,37 uniform-
ly pleasing the personnel at hospitals visited by the trans-
plantation teams. 
Preservation by Continuous Perfusion 
After removal, organs harvested with these techniques can 
be packed in ice chests and kept in special cold solutions 
near 0 °C until transplantation. The heart, liver, and kidneys 
can remain cold-packed within pre-procedure time limits 
of six, eight, and 48 hours, respectively. Sophisticated tech-
niques for continuous perfusion of all these organs have 
been developed, but have been widely used only for kidney 
grafts. The perfusion technique for kidneys, described by 
Belzer et al,38 uses an asanguineous and oncotically con-
trolled fluid. Though the method is a good one, the quality 
of preservation in the first two days is not markedly better 
than that achieved wi th the simpler infusion and "slush" 
method, whereby the organs are simply refrigerated after 
the initial cooling with special chilled solutions. 
Better continuous perfusio n techniques should permit 
the extension of perservation times of all organs; however, 
experimental efforts a t continuous perfusion of hearts and 
livers usually have yielded resul ts inferior to those with the 
simple infusion and refrigeration methods. 
Tissue Typing 
Twenty-five years ago when transplantation was in its infan-
cy, it was predicted that tissue matching would have to be 
perfected if the new gra fting technology was to succeed. 
Since then, the validity o f tissue matching, its genetic basis, 
and, above all, its complexity have become increasingly 
recognized . 
The value of tissue matching for transplantation between 
family members has been established beyond any doubt. 
At the same time, the very complexity of the human histo-
compatibility system has militated against easy match ing 
between nonrelated people. At a practical level, close 
matching for transplantation of cadaver kidneys has 
. become less of a consideration, especially since the avail-
ability of cyciosporine.With transplantation of the liver, 
heart, and other extrarenal organs, tissue matching has not 
even been taken into consideration since the events leading 
to and connected with transplantation occur so quickly that 
a labored search for a well-matched organ is not possible. 
Surprisingly, good results can be obtained even with com-
pletely mismatched cadaver organs, and this fact has 
reduced progressive emphasis on antigen matching. 
However, none of the immunosuppressive measures 
available today can prevent the immediate destruction of 
transplanted kidneys by preformed humoral antibodies in 
a condition that has been called "hyperacute rejection." 
Terasaki et aP9 described the first example of this pheno-
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menon in 1965, with prompt confirmation by Kissmeyer-
Nielsen40 of Denmark and by many others. Hyperacute 
rejection is most commonly seen with kidney transplants, 
but the heart and liver (in that order of susceptibility) can 
also be similarly destroyed. Hyperacute rejection can be 
avoided by the so-called crossmatch test, which detects anti-
donor antibodies in the recipient's serum before the proce-
dure. Crossmatching has proved to be the single most 
important practical contribution of tissue typers to the 
practice of transplantation during the last quarter cent ury. 
Prospects of Improvement 
The prognosis for improved transplantation care hinges 
upon improvements in immunosuppression, organ pro-
curement and preservation, and tissue typing. 
The most urgent need in transplantation 
is improved organ preservation. The 
techniques in common use today were 
developed two decades ago and have not 
undergone fundamental change since then. 
There are hopes that immunosuppression can be im-
proved. New drugs are being evaluated, some of which are 
far more potent than cyclosporine. Whether these agents 
have acceptable toxicity limits, and t he extent to which they 
can be used in combination with other drugs, remains to 
be determined. The techniques for rapid assessment of 
drugs, including the most minute details of their mecha-
nisms of action, have been a part of a pharmaceutical 
industry revolution that is sure to produce other promising 
drugs. 
The most urgent need in transplantation is improved 
organ preservation. The techniques in common use today 
were developed two decades ago and have not undergone 
fundamental change since then. Worldwide linkage of 
donor networks would be possible overnight if ways could 
be found to store livers or hearts even for as long as one 
day. The prospects of this kind of breakthrough, though, 
are not bright at the present time. 
With tissue matching, the objective of finding perfect 
antigen matches at the principal histocompatibility loci has 
come to be less important because of the great advances 
in immunosuppression; however, identification of poten-
tially injurious preformed antibody states has become all 
the more important. Many examples of hyperacute rejec-
tion of kidneys, hearts, and even livers have occurred wit h-
out preprocedure identi fication of t he offending antibody 
system responsible for starting t he process. 
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Government Policies, Past and Present 
I n indispensable ways, government has played a central role 
in the development of transplantation; a remarkable pro-
portion of all such research in this field has been funded 
by the National Institutes of Health. When clinical trials 
were first attempted, the recipients of various organs (first 
kidneys, then livers, and finally hearts) were cared for on 
federally sponsored Clinical Research Center Wards. Renal 
transplantation was funded as a government service by 
Congress in 1973 with the creation of the End Stage Renal 
Disease Program, as well as t he Net wor k for Cadaver Organ 
Procurement, which remains in operation today. 
The latter program was one of the key advances in clinical 
organ transplantation since it encouraged identification 
and early referral of potential organ donors. This orderly 
process depends upon widespread social and legal accep-
tance of what is known as brain death or, more precisely, 
irreversible central nervous system injury. 
The clinical criteria of brain death have been extremely 
well standardized since 1968. Once the diagnosis of brain 
death has been established, the attending physician or neu-
rologist can formally pronounce death in the patient's chart 
and can complete a death certificate even though the pa-
tient's circulation is intact. It is then possible, and in many 
states it is a legal requirement, to formally request consent 
for organ donation from the family. The physician should 
also determine that the relatives have a complete under-
standing of the diagnosis of brain death and the organ pro-
rllr~ment process. Legislation giving legal sanction to the 
concept 01 brain death has been passed in 44 states and 
judicial precedents have been established in six other 
states .J1 
The shortage of suitable donor organs has prompted a 
new kind of legislative initiative called required request. 
These laws, which have been passed in almost all states, 
mandate each hospital to systematically approach the fami-
lies of all donors who die under circumstances that might 
permit solid organ or tissue donation. 
Support of organ donor programs has come from gov-
ernment leaders, most notably President Ronald Reagan, 
who has stressed the importance of private sector participa-
tion, even including the Boy Scouts of America in their 
Presidential Good Turn program. 
These laws and other activities illustrate the support of 
both the state and federal governments in disseminating 
news to the public on the advantages of transplantation. 
Congress enacted legislation in 1984 that authorized a t?sk 
force to study issues in organ procurement and distribu-
tion . The government then authorized the eventual funding 
of the United Organ Sharing Network (UNOS) by awarding 
this previously private organization a contract to operate 
a computer matching system to aid in the placement of 
renal and extrarenal organs in a systematic fashion . In addi-
tion, UNOS has been asked to look into the collection of 
careful data on all renal and extrarenal organs procured. 
For extrarenal organs, UNOS presently acts in an advi-
sory capacity by supplying a prioritized list of acceptable 
recipients to the organ procurement agency that is manag-
ing a specific donor. The final choice for utilization of avail-
able organs is made by the local procurement agency. At 
the present time, UNOS has many subcommittees at work 
developing recommendations for the efficient and fair dis-
tribution of organs. Many of these conditions will be pro-
scribed by the limitations of preservation technology, which 
is too underdeveloped at present to permit extensive and 
time-consuming traffic of organs from city to city under 
any but the most urgent conditions. 
The current trend of high legislative 
interest and activity in regulating 
transplantation could ultimately stifle the 
orderly progress and growth of this 
important branch of medicine. 
Parallel to the rapidly growing success of organ trans-
plantation has been an increasing interest in the regulation 
o f transplantation medicine by state and federal govern-
ments. The transplantation community has attempted to 
collaborate with government in the development of new 
health policies; the current trend of high legislative interest 
and activity in regulating transplantation could ultimately 
stifle the orderly progress and growth of this important 
branch of medicine. Future emphasis in these efforts must 
be on the establishment of a climate of constructive col-
laboration, and not government domination or control of 
what primarily must remain a professional medical effort. 
Media factors have encouraged public acceptance of 
transplantation as a fully established discipline, ready for 
mass clinical application. This deep misunderstanding of 
the complexity of organ transplantation and related prob-
lems has generated ambitious and sometimes premature 
legislation concerning organ retrieval and sharing, not ta k-
ing into account that organ preservation is ten to 15 years 
behind proposed federal regulations. 0 
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Dr Starzl will be honored by the International Organ Trans· 
plant Forum in September for his 25 years of research and 
clinical achievement. 
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